<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01034345</url>
  </required_header>
  <id_info>
    <org_study_id>Sirolimus_Liver_Tolerance</org_study_id>
    <nct_id>NCT01034345</nct_id>
  </id_info>
  <brief_title>Effect of Rapamycin on Tolerance-related Biomarkers on Stable Liver Transplant Recipients</brief_title>
  <official_title>Effect of Rapamycin on Tolerance-related Biomarkers on Stable Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In contrast to calcineurin inhibitors, sirolimus is known to exert remarkable&#xD;
      tolerance-promoting properties in multiple animal transplant models. Whether sirolimus is&#xD;
      capable of enhancing tolerance-related pathways and/or promoting complete withdrawal of&#xD;
      immunosuppressive drugs in human transplant recipients has not been previously addressed. The&#xD;
      goal of the investigators study is to evaluate the effects of sirolimus on previously&#xD;
      identified tolerogenic pathways in humans and, indirectly, to assess the capacity of this&#xD;
      drug to enhance the proportion of liver recipients undergoing successful immunosuppression&#xD;
      weaning.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:To test in liver transplant recipients identified as non-tolerant whether&#xD;
      discontinuation of calcineurin inhibitors followed by 6-month treatment with sirolimus&#xD;
      modifies the pattern of expression of the set of genes associated with tolerance&#xD;
&#xD;
      Background: Sirolimus is an immunosuppressive drug used to counter autoimmunity and to&#xD;
      prevent acute graft rejection in human and has remarkable tolerance-promoting properties in&#xD;
      animal transplant models.&#xD;
&#xD;
      Hypothesis/Specific Aims:We hypothesize that sirolimus promotes tolerogenic pathways in human&#xD;
      liver transplantation.&#xD;
&#xD;
        1. To test in liver transplant recipients identified as non-tolerant whether&#xD;
           discontinuation of calcineurin inhibitors followed by 6-month treatment with sirolimus&#xD;
           modifies the pattern of expression of the set of genes associated with tolerance&#xD;
&#xD;
        2. To test in liver transplant recipients identified as non-tolerant whether conversion&#xD;
           from calcineurin inhibitors to sirolimus modifies memory type immune responses.&#xD;
&#xD;
        3. To test in liver transplant recipients identified as non-tolerant whether conversion&#xD;
           from calcineurin inhibitor monotherapy to sirolimus affects the frequency, phenotype and&#xD;
           function of potentially immunoregulatory peripheral blood lymphocyte subsets&#xD;
&#xD;
        4. To test in liver transplant recipients identified as non-tolerant whether conversion&#xD;
           from calcineurin inhibitors to sirolimus promotes epigenetic changes related to&#xD;
           immunoregulation and cancer development/progression&#xD;
&#xD;
      Proposed Methods:Gene expression experiments: we will quantify the expression in peripheral&#xD;
      blood of a set of genes previously identified as predictive of successful immunosuppression&#xD;
      withdrawal in stable liver transplant recipients. Blood samples will be obtained before and 6&#xD;
      months after conversion to sirolimus treatment. Measurement of gene expression levels will be&#xD;
      conducted employing real-time TaqMan PCR. Classification of patients in the&#xD;
      tolerant/non-tolerant categories will be conducted utilizing thresholds and predictive&#xD;
      algorithms developed in our laboratory.&#xD;
&#xD;
      Immunophenotyping studies: we will quantify in peripheral blood various mononuclear cell&#xD;
      subsets implicated in immunoregulatory pathways before and 6 months after conversion to&#xD;
      sirolimus treatment. Measurements will be conducted employing flow cytometry.&#xD;
&#xD;
      Functional assays: we will isolate CD4+CD25+ regulatory T cells (Treg) from peripheral blood&#xD;
      by Sorter before and 6 months after conversion to sirolimus treatment. Serial dilution&#xD;
      experiments will be conduct in an antigen non-specific assay to assess the relative&#xD;
      suppressive properties of Tregs. IFNg ELISpot assays will be conducted in parallel employing&#xD;
      peripheral blood mononuclear cells as responder cells to measure donor-specific alloimmune&#xD;
      responses.&#xD;
&#xD;
      Measurement of DNA-methylation: recipient DNA will be extracted from peripheral blood samples&#xD;
      before and after 6-month sirolimus treatment and used to conduct whole-genome methylation&#xD;
      studies employing the ILLUMINA array platform.&#xD;
&#xD;
      Expected results: We expect to precisely define the effects of sirolimus on previously&#xD;
      identified tolerogenic pathways in humans and, to assess the capacity of this drug to enhance&#xD;
      the proportion of liver recipients undergoing successful immunosuppression weaning.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">November 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of conversion from calcineurin inhibitors to sirolimus on tolerance-related biomarkers of tolerance in human liver transplant recipients.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this arm will discontinue maintenance immunosuppression based on calcineurin inhibitors and start treatment with sirolimus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcineurin inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this arm will keep the same maintenance immunosuppression based on calcineurin inhibitors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Switch from calcineurin inhibitor maintenance immunosuppression to sirolimus treatment at the doses needed to reach trough blood levels 8-15 ng/mL.</description>
    <arm_group_label>Sirolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcineurin inhibitor</intervention_name>
    <description>Patients will maintain the same immunosuppressive regimen based on calcineurin inhibitors. No modifications in the treatment will be conducted.</description>
    <arm_group_label>Calcineurin inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years and weight ≥ 40 kg&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test result&#xD;
             before random assignment and must agree to use a medically acceptable method of&#xD;
             contraception throughout the treatment period and for 3 months after discontinuation&#xD;
             of randomly assigned treatment. Any woman becoming pregnant during the treatment&#xD;
             period must withdraw from the study&#xD;
&#xD;
          -  Subjects receiving immunosuppressive therapy with a stable regimen of calcineurin&#xD;
             inhibitor or a combination of calcineurin inhibitor with corticosteroids and/or&#xD;
             antimetabolite therapy for a minimum of 4 weeks prior to randomization&#xD;
&#xD;
          -  Recipient of a liver transplantation with &gt;3 years follow-up Cockcroft-Gault GFR&#xD;
             values ≥ 40 mL/min&#xD;
&#xD;
          -  Total white blood cell count &gt;3.0 x 109/L (&gt;3,000/mm3), platelet count &gt;75 x109/L&#xD;
             (&gt;75,000/mm3), fasting triglycerides &lt;3.95 mmol/L (&lt;350 mg/dL), fasting cholesterol&#xD;
             &lt;7.8 mmol/L (&lt;300 mg/dL). If subjects are currently untreated for elevated cholesterol&#xD;
             and/or triglycerides and are excluded from the study based on the above criteria,&#xD;
             subjects will be offered antihyperlipidemic therapy.&#xD;
&#xD;
          -  Stable liver function defined as: a) normal liver function tests (AST, ALT, ALP, GGT)&#xD;
             during the previous 6 months; or alternatively b) minor alterations in liver function&#xD;
             tests that have not changed over the previous 6 months (AST/ALT &lt; 2 fold normal&#xD;
             levels; ALP &lt; 1.5 fold normal levels; GGT &lt; 3 fold normal levels; bilirubin &lt; 3&#xD;
             mg/dL).&#xD;
&#xD;
          -  Absence of treatment with interferon for hepatitis C virus infection&#xD;
&#xD;
          -  Absence of autoimmune diseases requiring immunosuppressive therapy&#xD;
&#xD;
          -  Absence of autoimmune liver disease as indication for transplantation&#xD;
&#xD;
          -  Absence of any rejection episodes in the 12 previous months&#xD;
&#xD;
          -  Peripheral blood gene expression profile characteristic of non-tolerant recipients&#xD;
             (likelihood of successful weaning &lt;5%)&#xD;
&#xD;
          -  Written, signed, and dated IRB- or IEC-approved informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requirement for treatment with immunosuppressive drugs for any indications other than&#xD;
             prevention of rejection&#xD;
&#xD;
          -  Proteinuria levels &gt; 0.8 g/day&#xD;
&#xD;
          -  Evidence of systemic infection (e,g., sepsis, bacteremia, pneumonia, etc.) at time of&#xD;
             random assignment.&#xD;
&#xD;
          -  History of documented human immunodeficiency virus infection.&#xD;
&#xD;
          -  Hypercoagulable states or any history of deep vein thrombosis, HAT, or portal vein&#xD;
             thrombosis. (Exception: incidental vascular thrombosis at the time of liver explant,&#xD;
             which in the opinion of the investigator, does not place the subject at increased risk&#xD;
             of thrombotic events.)&#xD;
&#xD;
          -  Transplant of other graft in addition to the liver&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Sanchez Fueyo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic Barcelona/IDIBAPS, University of Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alberto Sanchez-Fueyo, M.D</last_name>
    <phone>34-932275400</phone>
    <phone_ext>2844</phone_ext>
    <email>afueyo@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona, University of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Sanchez-Fueyo, MD</last_name>
      <phone>34-93-2275400</phone>
      <phone_ext>2844</phone_ext>
      <email>afueyo@clinic.ub.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>December 16, 2009</study_first_submitted>
  <study_first_submitted_qc>December 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2009</study_first_posted>
  <last_update_submitted>December 16, 2009</last_update_submitted>
  <last_update_submitted_qc>December 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Alberto Sanchez-Fueyo</name_title>
    <organization>Hospital Clinic Barcelona/ IDIBAPS</organization>
  </responsible_party>
  <keyword>Sirolimus</keyword>
  <keyword>Liver Transplantation</keyword>
  <keyword>Tolerance</keyword>
  <keyword>Immune responses</keyword>
  <keyword>Allograft tolerance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

